Trial
NCT03765983
GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Dana-Farber Cancer Institute
Collaborators
Kazia Therapeutics Limited
Condition
Breast Cancer
Intervention
Trastuzumab
Why stopped
participants are no longer being examined or receiving intervention
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-27